These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3467873)

  • 1. In vitro assessment of CI-934--a new quinolone derivative.
    Finch R; Martin J; Pilkington R
    Chemioterapia; 1986 Dec; 5(6):368-74. PubMed ID: 3467873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antibacterial activity of enoxacin, a new pyridonecarboxylic acid.
    Fabio U; Bondi M; Galletti F; Manicardi G; Messi P; Neglia R; Casolari C
    Boll Ist Sieroter Milan; 1987; 66(2):110-5. PubMed ID: 3478050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria.
    van der Auwera P; Vandermies A; Grenier P; Klastersky J
    Drugs Exp Clin Res; 1987; 13(3):125-32. PubMed ID: 3622241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
    Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of CI-934 and other antimicrobial agents against gram-positive and gram-negative bacteria.
    Smith RP; Baltch AL; Hammer MC; Conroy JV
    Clin Ther; 1986; 9(1):106-18. PubMed ID: 3815456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ciprofloxacin against gram-positive cocci.
    Barry AL; Jones RN
    Am J Med; 1987 Apr; 82(4A):27-32. PubMed ID: 3578323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
    Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
    J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Cullmann W; Stieglitz M; Baars B; Opferkuch W
    Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of the new quinolone WCK 771 against pneumococci.
    Appelbaum PC; Pankuch GA; Bozdogan B; Lin G; Jacobs MR; Patel MV; Gupte SV; Jafri MA; De Souza NJ; Khorakiwala HF
    Clin Microbiol Infect; 2005 Jan; 11(1):9-14. PubMed ID: 15649298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agents.
    Kim MJ; Weiser M; Gottschall S; Randall EL
    J Clin Microbiol; 1987 May; 25(5):787-90. PubMed ID: 3108309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of CI-934, a new quinolone antimicrobial, against gram-positive bacteria.
    Eliopoulos GM; Reiszner E; Caputo GM; Moellering RC
    Diagn Microbiol Infect Dis; 1986 Nov; 5(4):341-4. PubMed ID: 3096629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R; Andrews JM; Danks G
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiograms of pathogenic bacteria isolated from laboratory animals.
    Owens DR; Wagner JE; Addison JB
    J Am Vet Med Assoc; 1975 Oct; 167(7):605-9. PubMed ID: 240789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro assessment of lomefloxacin (SC-47111)--a new quinolone derivative.
    Finch R; Martin J; Pilkington R
    J Antimicrob Chemother; 1988 Dec; 22(6):881-4. PubMed ID: 3243735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of simulated blood cultures for antibiotic effect on time to detection of the two blood culture systems BacT/ALERT and BACTEC 9240.
    Viganò EF; Vasconi E; Agrappi C; Clerici P; Melloni P
    New Microbiol; 2004 Jul; 27(3):235-48. PubMed ID: 15460526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative determination of minimal inhibitory and bactericidal concentrations of ciprofloxacin, cefotaxime and HR 810 for gram-negative bacteria either sensitive or resistant to ureidopenicillins and/or gentamicin.
    Bartmann K; Tarbuc R
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 May; 259(3):378-89. PubMed ID: 2931927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.